Literature DB >> 21205460

Smokers and non smokers with rheumatoid arthritis have similar clinical status: data from the multinational QUEST-RA database.

A Naranjo1, S Toloza, I Guimaraes da Silveira, J Lazovskis, M L Hetland, H Hamoud, T Peets, H Mäkinen, L Gossec, G Herborn, F N Skopouli, B Rojkovich, A Aggarwal, P Minnock, M Cazzato, H Yamanaka, O Oyoo, S Rexhepi, D Andersone, A Baranauskaite, N Hajjaj-Hassouni, J W G Jacobs, G Haugeberg, S Sierakowski, R Ionescu, D Karateew, A Dimic, D Henrohn, F Gogus, H Badsha, E Choy, M Bergman, T Sokka.   

Abstract

OBJECTIVES: To analyse clinical severity/activity of rheumatoid arthritis (RA) according to smoking status.
METHODS: The QUEST-RA multinational database reviews patients for Core Data Set measures including 28 swollen and tender joint count, physician global estimate, erythrocyte sedimentation rate (ESR), HAQ-function, pain, and patient global estimate, as well as DAS28, rheumatoid factor (RF), nodules, erosions and number of DMARDs were recorded. Smoking status was assessed by self-report as 'never smoked', 'currently smoking' and 'former smokers'. Patient groups with different smoking status were compared for demographic and RA measures.
RESULTS: Among the 7,307 patients with smoking data available, status as 'never smoked,' 'current smoker' and 'former smoker' were reported by 65%, 15% and 20%. Ever smokers were more likely to be RF-positive (OR 1.32;1.17-1.48, p<0.001). Rheumatoid nodules were more frequent in ever smokers (OR 1.41;1.24-1.59, p<0.001). The percentage of patients with erosive arthritis and extra-articular disease was similar in all smoking categories. Mean DAS28 was 4.4 (SD 1.6) in non-smokers vs. 4.0 (SD 1.6) in those who had ever smoked. However, when adjusted by age, sex, disease duration, and country gross domestic product, only ESR remained significantly different among Core Data Set measures (mean 31.7mm in non-smokers vs. 26.8mm in ever smoked category).
CONCLUSIONS: RA patients who had ever smoked were more likely to have RF and nodules, but values for other clinical status measures were similar in all smoking categories (never smoked, current smokers and former smokers).

Entities:  

Mesh:

Year:  2011        PMID: 21205460

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

1.  The Effect of Tobacco Smoking on Musculoskeletal Health: A Systematic Review.

Authors:  Ahmad M Al-Bashaireh; Linda G Haddad; Michael Weaver; Debra Lynch Kelly; Xing Chengguo; Saunjoo Yoon
Journal:  J Environ Public Health       Date:  2018-07-11

2.  Results of a specific smoking cessation program for patients with arthritis in a rheumatology clinic.

Authors:  Antonio Naranjo; Ana Bilbao; Celia Erausquin; Soledad Ojeda; Félix M Francisco; Iñigo Rúa-Figueroa; Carlos Rodríguez-Lozano
Journal:  Rheumatol Int       Date:  2013-09-05       Impact factor: 2.631

3.  Metabolic syndrome in rheumatoid arthritis: case control study.

Authors:  Samira Rostom; Mariam Mengat; Racha Lahlou; Asmaa Hari; Rachid Bahiri; Najia Hajjaj-Hassouni
Journal:  BMC Musculoskelet Disord       Date:  2013-04-26       Impact factor: 2.362

4.  Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway.

Authors:  Glenn Haugeberg; Inger Johanne Widding Hansen; Dag Magnar Soldal; Tuulikki Sokka
Journal:  Arthritis Res Ther       Date:  2015-08-20       Impact factor: 5.156

5.  Factors influencing erythrocyte sedimentation rate in adults: New evidence for an old test.

Authors:  Vanessa Alende-Castro; Manuela Alonso-Sampedro; Nuria Vazquez-Temprano; Carmen Tuñez; Daniel Rey; Carmen García-Iglesias; Bernardo Sopeña; Francisco Gude; Arturo Gonzalez-Quintela
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

6.  Relationship Between Smoking and Structural Damage, Autoimmune Antibodies, and Disability in Rheumatoid Arthritis Patients.

Authors:  Filiz Sivas; Fatma Gül Yurdakul; Ayşegül Kiliçarslan; Semra Duran; Bedriye Başkan; Hatice Bodur
Journal:  Arch Rheumatol       Date:  2017-05-25       Impact factor: 1.472

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.